Press Releases: 2013

MiRacle Consortium led by InteRNA Technologies and VU University Medical Center Along with Quiet Therapeutics Receives a € 1.2 million FP7 Grant from the European Union

November 04, 2013
- Therapeutic development of cancer cell-specific targeting of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer - acronym: MiRacle - Nijmegen/Utrecht and Amsterdam (the Netherla...
Read more

ISA Pharmaceuticals Initiates Phase I/II Clinical Trial With ISA101 in Women with Cervical Cancer

October 29, 2013
- Therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) tested together with chemotherapy in women with HPV16-positive advanced or recurrent cervical cancer - Leiden, The Netherlands, October 29...
Read more

Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies

October 23, 2013
- Invention provides unique technology base for therapeutic human bispecific antibodies - Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes Utrecht, The Netherl...
Read more

ISA Pharmaceuticals Establishes Advisory Board

October 15, 2013
- Renowned Specialists to Support Development of ISA's Advancing Pipeline - Leiden, The Netherlands, October 15, 2013 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationall...
Read more

Merus Secures €31 Million in Series B Round Extension

October 03, 2013
Investment brings Series B to a total of €47.6 million Johnson and Johnson Development Cooperation joins as new investor; receives board seat Utrecht, The Netherlands, October 3, 2013 - Merus B.V., a bioph...
Read more

ISA Pharmaceuticals Presents Novel Data at the European Cancer Congress 2013: Strong Synergies Between Cancer Vaccine ISA101 and Chemotherapy

September 30, 2013
Chemotherapy improves immune response to therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) Leiden, The Netherlands, September 30, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmac...
Read more

ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia (AIN)

September 16, 2013
Therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) tested in HIV-positive male patients Leiden, The Netherlands, September 16, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmaceuti...
Read more

ORCA Therapeutics strengthens Scientific Advisory Board

September 05, 2013
Amsterdam, The Netherlands - September 3th, 2013 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announced today that it has expanded its Scientific...
Read more

ISA Pharmaceuticals Strengthens Management Team

July 08, 2013
Company hires Jan Fagerberg as Chief Medical Officer and Jens Hennecke as Chief Business Officer Ronald Loggers becomes Acting Chief Executive Officer and Gerard Platenburg Chief Operating Officer Leiden, Th...
Read more

Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013

June 17, 2013
Clinical Candidate Designed for the Treatment of Acute Myeloid Leukemia (AML) Utrecht, The Netherlands, June 17, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeu...
Read more

SUPPRESTEM Consortium Led by Merus Receives €6 Million FP7 Grant from the European Union

May 27, 2013
Development of Therapeutic Bispecific Antibodies (Biclonics™) Targeting Treatment-resistant Cancer Stem Cells Using Patient-Derived Organoid Screening Tools Utrecht, The Netherlands, May 27, 2013 - Merus B....
Read more

Novel AMPLIVANT™ Technology Introduced at AACR Annual Meeting 2013

April 12, 2013
AMPLIVANT™ TLR-ligand adjuvant to improve immunotherapies Leiden, The Netherlands, April 9, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed ther...
Read more

InteRNA Technologies secures additional equity financing to progress lead program for melanoma treatment

March 26, 2013
Utrecht/Amsterdam, The Netherlands, March 26, 2013 - InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing...
Read more

Merus Further Expands R&D Capacity

March 07, 2013
Company Contracts R&D Service Provider FairJourney Biologics Utrecht, The Netherlands, March 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today annou...
Read more

Merus Achieves Milestone with Novartis Option Fund

February 07, 2013
Company Reaches Milestone in Biclonics™ Program Partnered with Novartis Utrecht, The Netherlands, February 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutic...
Read more

OcellO and Merus sign agreement for screening bispecific cancer antibodies

January 14, 2013
Leiden and Utrecht, The Netherlands, January 14, 2013 - OcellO B.V. and Merus B.V. have entered into a collaboration under which OcellO will provide screening services to Merus. OcellO will use its 3D cell c...
Read more

ISA Pharmaceuticals Secures EUR 8 Million Funding

January 08, 2013
Leiden, the Netherlands, January 7, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infect...
Read more

Merus Selects Clinical Candidate for the Treatment of Acute Myeloid Leukemia (AML)

January 07, 2013
Utrecht, The Netherlands, January 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has selected MCLA-117 as lead candidate for cli...
Read more

Home > Press Releases > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds